((自动化翻译由路透提供，请见免责声明 ))
9月12日 - ** Viridian Therapeutics 股价上涨 1.1%，报 20.02 美元，此前该公司股价超出预期。
** 该公司于周三晚些时候宣布定价 (link)，约1070万股，价格为18.75美元，优先股可转换为约130万股，总收益为2.25亿美元。
** 交易规模从计划的 (link) 1.5 亿美元增加到 2.25 亿美元。
** VRDN 公司的药物 veligrotug 在晚期研究中显著减轻了 (link) 甲状腺眼病(TED) 的症状，使其有望成为安进公司 大片疗法 Tepezza 的首个竞争对手，随后 VRDN 的股价在周二大涨约 32
** 周三股价再涨 5.6%，收于 19.80 美元
** 公司计划将募集资金净额用于推进临床开发项目和其他一般用途
** 已发行股票约 6,390 万股，市值约 13 亿美元
** 截至本周三，股价累计下跌约 9
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.